External traditional Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs and preparation method of external traditional Chinese medicine composition

Through the fumigation and washing of topical Chinese medicine compositions, Chinese medicine ingredients such as Astragalus and Angelica have been used to solve the problems of high cost and many side effects in the treatment of peripheral nerve toxicity caused by platinum drugs, achieving more efficient treatment effects and lower cost.

CN118924862APending Publication Date: 2024-11-12AFFILIATED HOSPITAL OF JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410988961.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing drug treatment for treating peripheral neurotoxicity caused by platinum drugs has problems such as high cost, many side effects and inconspicuous efficacy.

Method used

Provide a topical Chinese medicine composition, including Astragalus, Angelica, Vinegar Triangle, Vinegar Curcuma, Cinnamon, Acetachoba and Gundamolone, which is used by fumigation and washing, and is prepared by decoction and filtration to make a decoction solution. , used to treat peripheral neurotoxicity caused by platinum drugs.

Benefits of technology

It reduces side effects during treatment, improves treatment effect, reduces the treatment cost of patients, delays the development of the disease, and avoids the side effects caused by oral or intravenous medication.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924862A_ABST
    Figure CN118924862A_ABST
Patent Text Reader

Abstract

The invention provides an external traditional Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs, and relates to the field of traditional Chinese medicines, and the external traditional Chinese medicine composition comprises astragalus membranaceus, angelica sinensis, vinegar-processed rhizoma sparganii, vinegar-processed curcuma zedoary, cassia twig, achyranthes bidentata and pheretima. The mass ratio of the astragalus membranaceus to the angelica sinensis to the vinegar rhizoma sparganii to the vinegar curcuma zedoary to the cassia twig to the achyranthes bidentata to the pheretima is 6: 3: 2: 2: 2: 4: 2. The pharmaceutical composition can solve the problems that in the prior art, when medicines such as mecobalamin, reduced glutathione, amifostine, lipoic acid, a calcium-magnesium mixture and ganglioside are adopted for treating OIPN, the treatment cost is high, the number of side reactions is large, and the treatment effect is not prominent, the side reactions generated during OIPN treatment are reduced, and the treatment effect on OIPN is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to an external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs and a preparation method thereof. Background Art

[0002] Oxaliplatin, or L-OHP, is a third-generation platinum anti-tumor drug that is widely used in the treatment of digestive system tumors such as colorectal cancer and gastric cancer. Oxaliplatin is also an important component of the standard regimen for adjuvant chemotherapy of colorectal cancer and the first-line chemotherapy regimen for recurrent and metastatic colorectal cancer. As a new commonly used chemotherapy drug, oxaliplatin has good clinical efficacy and a high usage rate, and is especially suitable for the treatment of gastrointestinal tumors. However, the use of oxaliplatin can cause some adverse reactions, such as peripheral neuropathy, or OIPN, which is a common and unique adverse reaction after oxaliplatin chemotherapy. The most common symptoms include numbness, loss of proprioception, tingling, hyperalgesia or ectopic pain in the hands and feet. The incidence of peripheral neuropathy caused by oxaliplatin is extremely high, which affects the quality of life of patients and even affects the treatment of tumors.

[0003] At present, Western medicine treatment of OIPN mainly focuses on measures such as nerve nutrition, analgesia, and intervention of ion channels. The drugs used in clinical practice include methylcobalamin, reduced glutathione, amifostine, lipoic acid, calcium magnesium mixture, and gangliosides. The above therapeutic drugs have certain efficacy, but there are certain disadvantages, among which the most prominent ones are the high cost of the drugs, more side effects, and poor efficacy. Summary of the invention

[0004] In view of the above-mentioned problems, the present invention provides a topical Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs, which can solve the problems of high treatment cost, more side effects and poor efficacy when using drugs such as methylcobalamin, reduced glutathione, amifostine, lipoic acid, calcium magnesium mixture and ganglioside to treat OIPN in the prior art, thereby reducing the side effects generated during the treatment of OIPN and improving the treatment effect of OIPN.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is:

[0006] The present invention provides a Chinese medicine composition for external use for treating peripheral neurotoxicity caused by platinum drugs, comprising astragalus, angelica, vinegar-striped rhizome, vinegar-curcuma, cinnamon twig, Chinese rhizome and radix phellodendri; the mass ratio of the astragalus, the angelica, the vinegar-striped rhizome, vinegar-curcuma, the cinnamon twig, the Chinese rhizome and radix phellodendri is 6:3:2:2:2:4:2.

[0007] The external Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs provided by the present invention preferably comprises: the weight of the Astragalus membranaceus is 180 g; the weight of the Angelica sinensis is 90 g; the weight of the Vinegar Trillium is 60 g; the weight of the Vinegar Curcuma zedoaria is 60 g; the weight of the Cinnamomum cassia twig is 60 g; the weight of the Achyranthes bidentata is 120 g; and the weight of the Pheretima chinensis is 60 g.

[0008] The present invention provides a method for preparing a Chinese medicine composition for external use for treating peripheral neurotoxicity caused by platinum drugs, comprising the following steps:

[0009] S101: preparing a Chinese medicine composition for external use, comprising 180 g of Astragalus, 90 g of Angelica, 60 g of Vinegar Trillium, 60 g of Vinegar Curcuma, 60 g of Cinnamomum cassia, 120 g of Rhizoma Cyathulae and 60 g of Pheretima;

[0010] S102: soaking all the Chinese medicines included in the prepared external Chinese medicine composition in 2000 ml of cold water, boiling them for the first time at 80° C., boiling them for 30 minutes, and filtering them for the first time to obtain a first medicine liquid and medicine residues;

[0011] S103: Replace 1000 ml of water, put the medicinal residue into the replaced water, and boil again at 80° C. After boiling for 30 minutes, filter again to obtain a second medicinal solution;

[0012] S104: Mix the first medicinal liquid and the second medicinal liquid to obtain a decoction.

[0013] In the method for preparing the external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided by the present invention, preferably, in step S102, the Chinese medicine is immersed in cold water for 30 minutes.

[0014] The above technical solution has the following advantages or beneficial effects:

[0015] The topical Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided by the present invention, also known as the blood-activating and stasis-removing prescription, includes astragalus and angelica, which are drugs for promoting blood circulation and removing stasis, and can increase the blood flow of local circulation, thereby promoting the establishment of collateral circulation; at the same time, astragalus and angelica can inhibit platelet aggregation, increase the deformability of red blood cells, and improve the hypoxia tolerance of peripheral tissues, which is beneficial to accelerate nerve repair and conduction. In the topical Chinese medicine composition, astragalus, an important medicine for replenishing qi, is reused, and astragalus is used to replenish qi and relieve numbness; while angelica is pungent and warms the body, and is an important medicine for promoting blood circulation and qi. Astragalus and angelica are used together to replenish qi and produce blood;

[0016] Including cinnamon twig, which is pungent, dispersing, warming and unblocking, and has the effects of warming and unblocking the meridians, dispersing cold and relieving pain. Astragalus combined with cinnamon twig can replenish qi and unblock yang, consolidate the exterior without retaining evil, and nourish the middle and unblock;

[0017] Including vinegar-cured Curcuma zedoaria and vinegar-cured Trillium gracile, vinegar-cured Curcuma zedoaria and vinegar-cured Trillium gracile are used together to break up blood circulation, promote qi movement, eliminate accumulation and relieve pain.

[0018] Including Chinese Rhizoma Cynanchum, which can promote blood circulation and dissipate blood stasis;

[0019] It also includes Dilong, which is mobile and good at clearing the meridians. It can be used with Astragalus and Angelica to treat Qi deficiency and blood stasis.

[0020] The combination of the above-mentioned medicines can invigorate Qi and promote blood circulation, remove blood stasis and dredge collaterals, activate blood circulation and remove blood stasis without hurting vital energy, thereby promoting Qi and blood circulation and improving the stagnant state of blood.

[0021] When using the external Chinese medicine composition provided by the present invention for treating peripheral neurotoxicity caused by platinum drugs, the patient is usually fumigated;

[0022] Since there are more capillaries in the hands and feet, the treatment method of fumigating the limbs with the external Chinese medicine composition has a high absorption rate of the drug. In addition, since the feet have a relatively thick stratum corneum, which has a lower transport capacity and a strong storage effect, the external fumigation drug solution can reach a diffusion period of several days or longer at the low blood drug concentration peak after being absorbed by the skin, thereby ensuring that the drug continues to work.

[0023] The drug penetration effect of traditional Chinese medicine is to reach the acupuncture points through the foot skin and be absorbed through the pores so that the medicine can directly reach the diseased area. The external Chinese medicine composition can accurately act on the patient's diseased area by fumigation, thereby increasing the utilization rate of the medicine, and then maximizing the efficacy of the medicine, effectively delaying the development of the disease and curbing the deterioration of the disease.

[0024] The use of fumigation to absorb drugs can avoid the side effects of oral or intravenous medication on other chemotherapy drugs. Since the external Chinese medicine composition is used in the fumigation method, the drug penetration effect of the Chinese medicine is to reach the acupuncture points through the skin of the foot, and the drug is absorbed through the pores so that the drug reaches the diseased area directly, and the drug effect can accurately act on the patient's diseased area. The external Chinese medicine composition will not affect the internal environment of the body, thereby reducing complications caused by drugs;

[0025] Since the Chinese medicine used is relatively low in price, the external Chinese medicine composition has the advantages of being simple and cheap in clinical practice; and the external Chinese medicine composition is used in the form of fumigation and washing, which can further reduce the patient's resistance to treatment, thereby improving the patient's treatment compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The present invention and its features, configurations and advantages will become more apparent by reading the detailed description of non-limiting embodiments with reference to the following drawings. The same reference numerals indicate the same parts throughout the drawings. The drawings are not drawn to scale, but rather to illustrate the subject matter of the present invention.

[0027] Figure 1 This is a flow chart of a method for preparing a topical Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided in Example 2 of the present invention.

[0028] Figure 2 This is a comparison chart of rat weights in a pain behavior test experiment provided in Example 3 of the present invention.

[0029] Figure 3 This is a comparison chart of mechanical pain thresholds of rats in a pain behavior test experiment provided in Example 3 of the present invention.

[0030] Figure 4 This is a comparison chart of cold pain thresholds of rats in a pain behavior test experiment provided in Example 3 of the present invention.

[0031] Figure 5 This is a comparison chart of the contents of TNF-α, IL-6, IL-1β, and NGF in rat serum in an enzyme-linked immunosorbent assay experiment provided in Example 4 of the present invention.

[0032] Figure 6 This is a comparison diagram of the HE staining results of rat skin tissue in a rat plantar skin and nerve nodule tissue HE staining experiment provided in Example 5 of the present invention.

[0033] Figure 7 This is a comparison diagram of the HE staining results of rat nerve nodule tissue in a rat plantar skin and nerve nodule tissue HE staining experiment provided in Example 5 of the present invention. DETAILED DESCRIPTION

[0034] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, but they are not intended to limit the present invention.

[0035] Embodiment 1:

[0036] Example 1 of the present invention provides a Chinese medicine composition for external use for treating peripheral neuropathy caused by platinum drugs, comprising astragalus, angelica, vinegar-striped rhizome, vinegar-curcuma, cinnamon twig, Chinese rhizome and radix phellodendri; the mass ratio of astragalus, angelica, vinegar-striped rhizome, vinegar-curcuma, cinnamon twig, Chinese rhizome and radix phellodendri is 6:3:2:2:2:4:2.

[0037] The external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided in Example 1 of the present invention, also known as the blood-activating and stasis-removing prescription, includes astragalus and angelica, which are drugs for activating blood circulation and removing stasis, and can increase the blood flow of local circulation, thereby promoting the establishment of collateral circulation; at the same time, astragalus and angelica can inhibit platelet aggregation, increase the deformability of red blood cells, and improve the hypoxia tolerance of peripheral tissues, which is beneficial to accelerate nerve repair and conduction. In this external Chinese medicine composition, astragalus, an important medicine for replenishing qi, is reused, and astragalus replenishes qi and relieves numbness; while angelica is pungent and warms the body, and is an important medicine for activating blood circulation and promoting qi. Astragalus and angelica are used together to replenish qi and produce blood;

[0038] Including cinnamon twig, which is pungent, dispersing, warming and unblocking, and has the effects of warming and unblocking the meridians, dispersing cold and relieving pain. Astragalus combined with cinnamon twig can replenish qi and unblock yang, consolidate the exterior without retaining evil, and nourish the middle and unblock;

[0039] Including vinegar-cured Curcuma zedoaria and vinegar-cured Trillium gracile, vinegar-cured Curcuma zedoaria and vinegar-cured Trillium gracile are used together to break up blood circulation, promote qi movement, eliminate accumulation and relieve pain.

[0040] Including Chinese Rhizoma Cynanchum, which can promote blood circulation and dissipate blood stasis;

[0041] It also includes Dilong, which is mobile and good at clearing the meridians. It can be used with Astragalus and Angelica to treat Qi deficiency and blood stasis.

[0042] The combination of the above-mentioned medicines can invigorate Qi and promote blood circulation, remove blood stasis and dredge collaterals, activate blood circulation and remove blood stasis without hurting vital energy, thereby promoting Qi and blood circulation and improving the stagnant state of blood.

[0043] When using the external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided in Example 1 of the present invention, fumigation is usually adopted;

[0044] Since there are more capillaries in the hands and feet, the treatment method of fumigating the limbs with the external Chinese medicine composition has a high absorption rate of the drug. In addition, since the feet have a relatively thick stratum corneum, which has a lower transport capacity and a strong storage effect, the external fumigation drug solution can reach a diffusion period of several days or longer at the low blood drug concentration peak after being absorbed by the skin, thereby ensuring that the drug continues to work.

[0045] The drug penetration effect of traditional Chinese medicine is to reach the acupuncture points through the foot skin and be absorbed through the pores so that the medicine can directly reach the diseased area. The external Chinese medicine composition can accurately act on the patient's diseased area by fumigation, thereby increasing the utilization rate of the medicine, and then maximizing the efficacy of the medicine, effectively delaying the development of the disease and curbing the deterioration of the disease.

[0046] The use of fumigation to absorb drugs can avoid the side effects of oral or intravenous medication on other chemotherapy drugs. Since the external Chinese medicine composition is used in the fumigation method, the drug penetration effect of the Chinese medicine is to reach the acupuncture points through the skin of the foot, and the drug is absorbed through the pores so that the drug reaches the diseased area directly, and the drug effect can accurately act on the patient's diseased area. The external Chinese medicine composition will not affect the internal environment of the body, thereby reducing complications caused by drugs;

[0047] Since the Chinese medicine used is relatively low in price, the external Chinese medicine composition has the advantages of being simple and cheap in clinical practice; and the external Chinese medicine composition is used in the form of fumigation and washing, which can further reduce the patient's resistance to treatment, thereby improving the patient's treatment compliance.

[0048] The external Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs provided in Example 1 of the present invention is preferably prepared with 180g of Astragalus, 90g of Angelica, 60g of Vinegar Trillium, 60g of Vinegar Curcuma, 60g of Cinnamomum cassia, 120g of Rhizoma Cyathulae, and 60g of Pheretima, which can have a good therapeutic effect on peripheral neuropathy (OIPN) caused by oxaliplatin (L-OHP) drugs.

[0049] Embodiment 2:

[0050] like Figure 1 As shown, Example 2 of the present invention provides a method for preparing a Chinese medicine composition for external use for treating peripheral neuropathy caused by platinum drugs as described in Example 1 of the present invention, comprising the following steps:

[0051] S101: preparing a Chinese medicine composition for external use, comprising 180 g of Astragalus, 90 g of Angelica, 60 g of Vinegar Trillium, 60 g of Vinegar Curcuma, 60 g of Cinnamomum cassia, 120 g of Rhizoma Cyathulae and 60 g of Pheretima;

[0052] S102: soaking all the Chinese medicines included in the prepared external Chinese medicine composition in 2000 ml of cold water, boiling them for the first time at 80° C., boiling them for 30 minutes, and filtering them for the first time to obtain a first medicine liquid and medicine residues;

[0053] S103: Replace 1000 ml of water, put the medicinal residue into the replaced water, and boil again at 80° C. After boiling for 30 minutes, filter again to obtain a second medicinal solution;

[0054] S104: Mix the first medicinal liquid and the second medicinal liquid to obtain a decoction.

[0055] The method for preparing the external Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs provided in Example 2 of the present invention, in step S101, when preparing the external Chinese medicine composition, 180g of Astragalus, 90g of Angelica, 60g of Vinegar Trillium, 60g of Vinegar Curcuma, 60g of Cinnamomum cassia, 120g of Rhizoma Cyathulae and 60g of Pheretima are taken as raw materials of the external Chinese medicine composition, and the configured external Chinese medicine composition is the optimal solution for the method for preparing the external Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs provided in Example 2 of the present invention;

[0056] In step S102, all the Chinese medicines included in the configured external Chinese medicine composition are soaked in 2000 ml of water; after soaking for a period of time, the Chinese medicines and the water after soaking are boiled at a temperature of 80° C.; after 30 minutes of boiling, the Chinese medicines and the liquid are filtered to obtain the residue and the first liquid medicine;

[0057] In step S103, the water used for soaking is replaced, and the drug residue filtered in step S101 is placed in the newly replaced 1000 ml water, and the drug residue and the replaced water are boiled at a temperature of 80° C. After 30 minutes of boiling, the drug residue and the liquid are filtered to obtain a second drug solution;

[0058] In step S104, the first medicinal liquid and the second medicinal liquid are mixed to form a decoction, thereby obtaining the external Chinese medicine composition (blood circulation and stasis removal prescription) for treating peripheral neuropathy caused by platinum drugs provided in Example 1 of the present invention.

[0059] In the method for preparing the external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs provided in Example 2 of the present invention, preferably, in step S102, the Chinese medicine is immersed in cold water for 30 minutes, and the immersion softens the Chinese medicine, thereby dissolving the active ingredients in the Chinese medicine in the medicinal tissue, which is conducive to the penetration and diffusion of the active ingredients into the cold water.

[0060] Embodiment 3:

[0061] A pain behavior test experiment provided in Example 3 of the present invention is used to reflect the efficacy of the external Chinese medicine composition (blood circulation and stasis removal prescription) in Example 1 of the present invention. The experimental content is as follows:

[0062] 1. Establishment of L-OHP (oxaliplatin)-induced chronic peripheral neurotoxicity (OIPN) colorectal cancer rat model:

[0063] L-OHP was intraperitoneally injected at a dose of 3 mg / kg / d (d refers to days) on days 1, 2, 3, 4, and 5 to establish an L-OHP chronic OIPN colorectal cancer rat model. The concentration of L-OHP was 1 mg / mL, and the total amount of drug injection within 5 days was 15 mg / kg. The model was considered successful when the rats in the L-OHP group showed symptoms of hyperalgesia such as unwillingness to move forward, lift their feet, add their feet, or even retreat, and decreased mechanical pain thresholds and cold thresholds.

[0064] 2. Experimental grouping and treatment:

[0065] (1) Blank control group (Control, n = 9 (n refers to the number of rats)): no treatment;

[0066] (2) OIPN model group (OIPN, n = 9): L-OHP was intraperitoneally injected at a dose of 3 mg / kg / d on days 1, 2, 3, 4, and 5 to establish a chronic OIPN rat model;

[0067] (3) Methylcobalamin group (methylcobalamin 0.135 mg / kg, n = 9): At the same time as L-OHP injection, rats were gavaged with methylcobalamin at a dose of 0.135 mg / kg / d from day 1 to day 21, once a day for a total of 21 days;

[0068] (4) Huoxue Huayu Decoction group (0.3 g / mL external soaking, n = 9): At the same time as L-OHP injection, rats were externally soaked with 0.3 g / mL Huoxue Huayu Decoction at 38-40°C from day 1 to day 21, once a day, at least 30 min each time, for a total of 21 days, with a soaking dose of 1000 mL each time;

[0069] (5) Huoxue Huayu Decoction + Methylcobalamin Group (0.3 g / mL external soaking + 0.135 mg / kg methylcobalamin, n = 9): At the same time as L-OHP injection, rats were externally soaked with 0.3 g / mL Huoxue Huayu Decoction at 38-40°C from day 1 to 21, once a day for at least 30 minutes each time, and 0.135 mg / kg / d methylcobalamin was gavaged once a day for a total of 21 days.

[0070] 3. Animal physiological index monitoring:

[0071] 3.1 Body weight measurement: The rats’ body weights were measured and recorded using an electronic scale in the morning on days 0, 3, 6, 9, 12, 15, 18, and 21.

[0072] 3.2 Determination of mechanical pain threshold: The mechanical pain threshold of the left lower limb was measured at 10:00 am on the 0th, 3rd, 6th, 9th, 12th, 15th, 18th, and 21st days. Test environment: A 20cm×20cm×10cm metal cage was placed on a metal frame platform. The rats were measured 1 hour after each treatment. The rats were first placed in a glass cage with a wire mesh at the bottom and waited for 30 minutes to adapt to the environment. Then, the rats were stimulated with Von Frey fibers at the left hind foot. The stimulation intensity started with 0.6g of fiber and gradually increased the force to bend the fiber until it exceeded the axis by 1 cm. If the rat did not retract its foot, a larger fiber was replaced until the rat retracted its foot. If the rat retracted its foot 3 times out of 5 stimulations, the stimulation intensity of this fiber was the effective intensity. Otherwise, it was the ineffective intensity. When a fiber with a certain stimulation intensity was the effective intensity for the experimental animal, a Von Frey fiber with a lower stimulation intensity was selected for stimulation until an ineffective intensity appeared. The minimum effective intensity was the stimulation response threshold of the limb.

[0073] 3.3 Cold pain threshold determination: The cold water bath tail removal method was used. The rats' tails were immersed in a water bath at 4°C on the morning of the 0th, 3rd, 6th, 9th, 12th, 15th, 18th, and 21st days until the tails were removed. The tail immersion time was recorded. The test was performed once every 5 minutes, and the test was repeated 3 times. The average value was calculated and recorded. The cut-off time was 15 seconds. The test values ​​of normal rats before treatment were used as normal reference values.

[0074] 4. Final collection:

[0075] 4.1 Preparation of whole blood samples: After 21 days of experimental intervention, the rats were fasted and allowed to drink water freely for 24 h. The body weight of each rat was measured, and the SD rats were anesthetized intraperitoneally with 30 mg / kg sodium pentobarbital. The abdominal skin of the rats was cut along the midline of the abdomen, and the peritoneum and fat were peeled off. The intestinal tissue was removed and the abdominal aorta was exposed. A disposable sterile blood collection needle was used to collect blood from the abdominal aorta of the rats. As much blood as possible was collected and stored at -80°C.

[0076] 4.2 Tissue preservation: Use a sterilized ceramic knife to peel off the nerves at the L4-L5 intervertebral foramen of the lumbar vertebrae, and obtain a total of 4 L4-L5 DRGs of rats; scrape the skin of the soles of the rats' limbs and feet and divide it into two parts for preservation: ① fix it in 4% paraformaldehyde solution for future use; ② store it at -80℃ for future use.

[0077] 5. Data processing and statistical methods:

[0078] The experimental data were expressed as mean ± standard error (Mean ± SEM), and all data were processed and statistically analyzed using GraphPad Prism 6. The comparison between the means of two groups of samples was performed using the t test, and the comparison between the means of multiple groups of samples was performed using the ANOVA test. P < 0.05 indicated that the difference was statistically significant.

[0079] The experimental results of the pain behavior test experiment provided in Example 3 of the present invention are as follows:

[0080] like Figure 2 As shown in the figure, compared with the normal control group (CN), the body weight of rats in the OIPN model group (MD), methylcobalamin group (MCBAN), Huoxue Huayu prescription group (HXHYD), and Huoxue Huayu prescription + methylcobalamin group (HXHYD + MCBAN) decreased significantly. Compared with the model group (MD), the body weight of rats in the methylcobalamin group (MCBAN) and Huoxue Huayu prescription + methylcobalamin group (HXHYD + MCBAN) increased significantly.

[0081] like Figure 3 As shown in the figure, compared with the normal control group (CN), the mechanical pain threshold of rats in the OIPN model group (MD) was significantly increased, indicating that the model was successfully established, and the rats showed neurotoxicity, numbness, sensory impairment, and insensitivity to pain and itch; compared with the OIPN model group (MD), the mechanical pain threshold of rats in the methylcobalamin group (MCBAN), the Huoxue Huayu Recipe group (HXHYD), and the Huoxue Huayu Recipe + methylcobalamin group (HXHYD + MCBAN) was significantly reduced, and the largest reduction was in the Huoxue Huayu Recipe + methylcobalamin group (HXHYD + MCBAN), followed by the methylcobalamin group (MCBAN), and then the Huoxue Huayu Recipe group (HXHYD). It can be seen that the combined use of Huoxue Huayu Recipe and methylcobalamin has the best effect, which can reduce the mechanical pain threshold of rats with sensory impairment and insensitivity to pain and itch, and make them feel pain.

[0082] like Figure 4 As shown in the figure, compared with the normal control group (CN), the cold pain threshold of rats in the OIPN model group (MD) was significantly increased, indicating that the model was successfully established, and the rats showed neurotoxicity, numbness, sensory impairment, and insensitivity to pain and itch; compared with the rats in the OIPN model group (MD), the cold pain threshold of rats in the methylcobalamin group (MCBAN), the Huoxue Huayu Recipe group (HXHYD), and the Huoxue Huayu Recipe + methylcobalamin group (HXHYD + MCBAN) was significantly reduced. The largest reduction was in the Huoxue Huayu Recipe + methylcobalamin group (HXHYD + MCBAN), followed by the methylcobalamin group (MCBAN), and then the Huoxue Huayu Recipe group (HXHYD). It can be seen that the combined use of Huoxue Huayu Recipe and methylcobalamin has the best effect, which can reduce the cold pain threshold of rats with sensory impairment and insensitivity to pain and itch, and make them feel cold.

[0083] From the above experimental results, it can be concluded that peripheral neuropathy caused by L-OHP is significantly treated with Huoxue Huayu Recipe, and the patient's symptoms will be relieved after treatment. Huoxue Huayu Recipe can improve the patient's neurotoxicity caused by L-OHP, increase the patient's treatment tolerance, and thus better treat tumors.

[0084] Embodiment 4:

[0085] L-OHP (oxaliplatin) can directly act on the target - dorsal root ganglia of the spinal cord, thereby causing damage and apoptosis of dorsal root ganglia of the spinal cord, glial cells, axons and peripheral nerves. TNF-α, IL-1β and IL-6 are upstream inflammatory factors of the MAPK signaling pathway. When pain sensitization occurs due to nerve damage, the expression of the three increases. The increase in TNF-α expression can lead to pain sensitization; when peripheral nerves are damaged, it can cause an increase in the expression level of IL-6 in the spinal cord; the early increase of TNF-α and IL-1β can promote the occurrence of pain sensitization, thereby activating the MAPK signaling pathway and causing the long-term existence and maintenance of neuropathic pain.

[0086] Nerve growth factor (NGF) is a typical neurotrophic factor that affects the development and survival of the nervous system. When L-OHP causes damage and apoptosis of spinal dorsal root ganglia, glial cells, axons and peripheral nerves, NGF expression increases, which is used to replenish nerve cell nutrition, regulate neurotransmitter synthesis, inhibit damage, and promote nerve regeneration and nerve function recovery.

[0087] Thus, an enzyme-linked immunosorbent assay (ELISA) experiment provided in Example 4 of the present invention can reflect the efficacy of the external Chinese medicine composition (blood circulation and stasis removal prescription) in Example 1 of the present invention through the content of TNF-α, IL-1β, IL-6 and NGF in serum. The experimental content is as follows:

[0088] 1. Experimental Materials

[0089] 1. Tissue Samples

[0090] Mouse serum samples were taken from the whole blood samples collected in Example 3, and were specifically grouped as follows:

[0091] (1) Blank control group (Control, n = 3)

[0092] (2) OIPN model group (n = 3)

[0093] (3) Methylcobalamin group (n=3)

[0094] (4) Huoxue Huayu prescription group (n=3)

[0095] (5) Huoxue Huayu Decoction + Methylcobalamin group (n = 3)

[0096] 2. Main Reagents

[0097] Normal saline (0.9% sodium chloride injection, Anhui Shuanghe Pharmaceutical Co., Ltd.)

[0098] PBS (Phosphate buffered saline, Nanjing Shengxing Biotechnology, SN331)

[0099] Rat TNF-α ELISA Kit (Wuhan Elior, E-EL-R2856)

[0100] Rat IL-6 ELISA Kit (Wuhan Elior, E-EL-R0015)

[0101] Rat IL-1β ELISA Kit (Wuhan Elior, E-EL-R0012)

[0102] Rat NGF ELISA Kit (Wuhan Elior, E-EL-R0652)

[0103] 3. Main instruments and equipment

[0104] Ultrapure water instrument (Millipore, USA, Milli-Q synthesis)

[0105] Clean bench (Sujing Group Antai Company, SW-CJ-1F)

[0106] -80℃ ultra-low temperature refrigerator (Aucma, DW-86L500)

[0107] 4℃ refrigerator (Qingdao Haier Group, BCD-416)

[0108] Analytical balance (MS-TS, METTLER, Switzerland)

[0109] 37℃ incubator (Beijing Fuyilian Medical Equipment, FYL-YS-50LK)

[0110] Centrifuge (Eppendorf, USA, 5417R)

[0111] Microplate reader (ThermoFisher, USA, Multiskan 51119000)

[0112] 2. Experimental Methods

[0113] 1. Sample Preparation

[0114] The whole blood sample is placed at room temperature for 1 hour or at 2-8°C overnight, then centrifuged at 2-8°C at 1000×g for 20 minutes, and the supernatant is taken for testing.

[0115] 2. Preparation of Reagents

[0116] (1) Reagent warming: First, place the reagent kit and the sample to be tested at room temperature 30 minutes before the experiment. If crystals appear in the concentrated washing solution, place it in a 37°C warm bath until all the crystals are dissolved.

[0117] (2) Gradient dilution of standard: The S0 standard with a concentration of 0 is regarded as a negative control or blank, and the standard is diluted in a gradient manner according to the instructions of the corresponding kit; the unused stock solution of the reconstituted standard should be discarded or divided into a single-use amount as needed and stored in a refrigerator at -20 to -80°C.

[0118] (3) Prepare washing buffer: Calculate the volume of the diluted washing buffer in advance, and then dilute the 20× washing buffer into 1× application solution with double distilled water or deionized water. Store the unused washing buffer in a refrigerator at 4°C.

[0119] (4) Washing method: shake off all liquid in the wells, fill each well with washing solution, let it stand for 1 min, then shake off all liquid in the wells, pat dry on absorbent paper, and wash the plate 5 times in this way.

[0120] 3. Detection steps

[0121] (1) After equilibration at room temperature for 20 min, take out the required strips from the aluminum foil bag and seal the remaining strips in a ziplock bag and place them back at 4°C.

[0122] (2) Set up standard wells and sample wells, and add 50 μl of standard of different concentrations to each standard well.

[0123] (3) First add 50 μl of the sample to be tested to the sample well. If the concentration of the sample to be tested is high, dilute it with diluent for a certain multiple before testing. Do not add any sample to the blank well.

[0124] (4) Except for the blank wells, add 100 μl of horseradish peroxidase (HRP)-labeled detection antibody to each well of the standard and sample wells, seal the wells with a sealing film, and incubate at 37°C in a water bath or incubator for 60 min.

[0125] (5) Discard the liquid, pat dry on absorbent paper, fill each well with washing solution, let it stand for 1 min, shake off the washing solution, pat dry on absorbent paper, and repeat this process 5 times; you can also use a plate washer to wash the plate here.

[0126] (6) Add 50 μl of substrate A and B to each well and incubate at 37°C in the dark for 15 min.

[0127] (7) Add 50 μl of stop solution to each well and measure the OD value of each well at the corresponding wavelength within 15 min.

[0128] 4. Result judgment

[0129] Draw a standard curve: In an Excel worksheet, use the standard concentration as the horizontal axis and the corresponding OD value as the vertical axis to draw a linear regression curve for the standard, and calculate the concentration value of each sample according to the curve equation.

[0130] 5. Data processing and statistical methods

[0131] The experimental data were expressed as mean ± standard error (Mean ± SEM), and all data were processed and statistically analyzed using GraphPad Prism 6. The comparison between the means of two groups of samples was performed using the t test, and the comparison between the means of multiple groups of samples was performed using the ANOVA test. P < 0.05 indicated that the difference was statistically significant.

[0132] The experimental results of the ELISA experiment provided in Example 4 of the present invention are as follows:

[0133] like Figure 5 As shown, compared with the blank control group (A), the levels of TNF-α, IL-6 and IL-1β in serum of the rats in the OIPN model group (B) were significantly increased, while the level of NGF was significantly decreased; compared with the OIPN model group (B), the levels of TNF-α, IL-6 and IL-1β in serum of the rats in the methylcobalamin group (C), the Huoxue Huayu recipe group (D) and the Huoxue Huayu recipe + methylcobalamin group (E) were gradually decreased, while the level of NGF was gradually increased; among them, the change in the Huoxue Huayu recipe + methylcobalamin group (E) was more obvious.

[0134] Compared with the blank group, the expression of inflammatory factors TNF-α, IL-6, and IL-1β in the serum of the model group rats after using L-OHP was significantly increased, which is consistent with the research on inflammatory factors and neuropathic pain. Methylcobalamin, Huoxue Huayu Fang, and Methylcobalamin + Huoxue Huayu Fang can effectively reduce the expression levels of inflammatory factors TNF-α, IL-6, and IL-1β in serum (P < 0.05); among them, the effect of Methylcobalamin + Huoxue Huayu Fang is better than that of Methylcobalamin, and the effect of Methylcobalamin is better than that of Huoxue Huayu Fang.

[0135] L-OHP can inhibit the secretion of NGF in rats, while methylcobalamin, Huoxue Huayu formula, and methylcobalamin + Huoxue Huayu formula can significantly increase the secretion of NGF (P < 0.05). Among them, the effect of methylcobalamin + Huoxue Huayu formula is better than that of methylcobalamin, and the effect of methylcobalamin is better than that of Huoxue Huayu formula.

[0136] From the above comparison results, it can be seen that the Huoxue Huayu recipe can effectively downregulate the expression levels of inflammatory factors TNF-α, IL-6, and IL-1β upstream of the MAKP signaling pathway in the serum of OIPN rat models and increase the secretion of NGF.

[0137] Embodiment 5:

[0138] Since L-OHP (oxaliplatin) can directly act on the target - dorsal root ganglia of the spinal cord, thereby causing damage and apoptosis of dorsal root ganglia and glial cells, axons and peripheral nerves, the dorsal root ganglia of the spinal cord is the primary nerve center for the nervous system to receive sensory signals. When neuropathic pain occurs, microglial cells in DRG proliferate rapidly and then change into an activated state, which usually lasts for several weeks. It can cause DRG cell apoptosis and also lead to many changes in apoptosis-related proteins, destroying the balance between cell apoptosis and cell proliferation cycle, thereby producing neurotoxic effects.

[0139] Therefore, the HE staining experiment of rat plantar skin and nerve tubercle tissue (DRG) provided in Example 5 of the present invention can reflect the efficacy of the external Chinese medicine composition (blood circulation and stasis removal prescription) in Example 1 of the present invention through the comparison of HE staining results. The experimental content is as follows:

[0140] 1. Experimental Materials

[0141] 1. Samples to be tested

[0142] Rat skin and nerve nodule tissues were taken from the tissues collected in Example 3 and were specifically grouped as follows:

[0143] (1) Blank control group (n=3)

[0144] (2) OIPN model group (n = 3)

[0145] (3) Methylcobalamin group (n=3)

[0146] (4) Huoxue Huayu prescription group (n=3)

[0147] (5) Huoxue Huayu Decoction + Methylcobalamin group (n = 3)

[0148] 2. Main Reagents

[0149] 4% paraformaldehyde (Beijing Boster, AR1069)

[0150] PBS (Nanjing Shengxing Biotechnology, SN331)

[0151] Paraffin slices (Beijing Solebow Technology Co., Ltd., YA0011)

[0152] Xylene (Sinopharm Chemical Reagent Co., Ltd., 10023418)

[0153] Anhydrous ethanol (Sinopharm Chemical Reagent Co., Ltd., 10009218)

[0154] Hematoxylin-eosin (HE) staining kit (Shanghai Biotech Biotechnology, C0105M)

[0155] Neutral gum (Beijing Solebow Technology Co., Ltd., G8590)

[0156] 3. Main instruments and equipment

[0157] Ultrapure water instrument (Millipore, USA, Milli-Q synthesis)

[0158] Tissue dehydrator (Shanghai Leica Instrument Co., Ltd., ASP300 )

[0159] Fully automatic embedding machine (Shanghai Leica Instrument Co., Ltd., EG1140H)

[0160] Paraffin slicer (Shanghai Leica Instrument Co., Ltd., RM2235)

[0161] Spreading machine (Shanghai Leica Instrument Co., Ltd., HI1210)

[0162] Slice baking machine (Shanghai Leica Instrument Co., Ltd., HI1220)

[0163] Oven (Shanghai Fuma Experimental Equipment Co., Ltd., DGX-9003B)

[0164] Optical microscope (Olympus, Japan, BX51)

[0165] 2. Experimental Methods

[0166] 1. Dehydration

[0167] The rat skin and nerve tubercle tissue were removed from the fixative and dehydrated in a dehydrator with gradient ethanol in sequence. The program was set as follows: 75% ethanol for 1 h → 85% ethanol for 1 h → 90% ethanol for 1 h → 95% ethanol for 1 h → anhydrous ethanol for 1 h → anhydrous ethanol for 1 h → xylene I for 30 min → xylene II for 30 min → paraffin I for 1 h → paraffin II for 1 h → paraffin III for 1 h.

[0168] 2. Embedding

[0169] (1) Place the melted paraffin into the embedding frame. Before the paraffin solidifies, take the tissue out of the dehydration box, place it in the embedding frame according to the embedding requirements, and attach the corresponding label.

[0170] (2) Place the wax block in a freezer at -20°C and cool it. After the wax block solidifies, remove it from the embedding frame and trim it.

[0171] (3) Place the embedded paraffin block in a 4°C refrigerator to set, and determine the setting time based on subsequent experiments.

[0172] 3. Slicing

[0173] (1) After 10 hours of fixation, take the tissue out of the 4°C refrigerator and fix it on the microtome. First, roughly adjust the slices to 1 mm thick, determine the tissue section, and then finely adjust the slices to 4 μm thick paraffin sections.

[0174] (2) Use tweezers to place the slices in 45°C constant temperature water and spread them out. After the slices are spread out flat, use a glass slide to remove the slices from the water, let them dry naturally, and then place them in a 37°C oven to dry.

[0175] 4. Staining

[0176] After drying, take it out of the oven and immediately perform HE staining according to the following steps: xylene I dewaxing for 5 min → xylene II dewaxing for 5 min → xylene III dewaxing for 5 min → xylene IV dewaxing for 5 min → anhydrous ethanol dehydration for 5 min → 90% ethanol dehydration for 5 min → 80% ethanol dehydration for 5 min → 70% ethanol dehydration for 5 min → tap water washing 3 times (immersion washing, 1 min each time) → hematoxylin staining for 5-10 min → tap water washing 2 times, 5 min each time → 1% hydrochloric acid alcohol differentiation for 5-10 s → tap water rinse for 10 min → eosin staining for 2-3 min → 70% ethanol dehydration for 10 s → 80% ethanol dehydration for 10 s → 90% ethanol dehydration for 10 s.

[0177] 5. Seal the slide

[0178] Dehydrate the stained sections in anhydrous ethanol twice, 2 minutes each time, and then put them in xylene to make them transparent twice, 5 minutes each time. Use neutral gum to seal the sections, and do not create bubbles when sealing.

[0179] 6. Take photos

[0180] The skin and nerve nodule tissue structures of rats in each group were observed under an optical microscope and photographed.

[0181] The experimental results of the HE staining experiment of rat plantar skin and nerve nodule tissue provided in Example 5 of the present invention are as follows:

[0182] like Figure 6 As shown, the HE staining results of the skin tissue of rats in each group were as follows: the cells of the blank control group (A) were neatly arranged, compact and orderly, and the cell size was normal; compared with the blank control group (A), the cell structure of the Huoxue Huayu Recipe + Mecobalamin group (E) was disordered, and there was inflammatory cell infiltration; compared with the Huoxue Huayu Recipe + Mecobalamin group (E), the cell structure of the Mecobalamin group (C) was disordered, and the infiltration of inflammatory cells increased; compared with the Mecobalamin group (C), the cell structure of the Huoxue Huayu Recipe group (D) was disordered, and the infiltration of inflammatory cells increased; compared with the Huoxue Huayu Recipe group (D), the cell structure of the OIPN model group (B) was disordered, and the infiltration of inflammatory cells increased.

[0183] like Figure 7As shown, the HE staining results of the nerve nodule tissues of the rats in each group were as follows: the cells of the blank control group (A) were neatly arranged, compact and orderly, and the cell size was normal; compared with the blank control group (A), the cells of the Huoxue Huayu Recipe + Mecobalamin group (E) were relatively disordered and had a loose structure; compared with the Huoxue Huayu Recipe + Mecobalamin group (E), the cells of the Mecobalamin group (C) were relatively disordered and had a loose structure; compared with the Mecobalamin group (C), the cells of the Huoxue Huayu Recipe group (D) were relatively disordered and had a loose structure; compared with the Huoxue Huayu Recipe group (D), the cells of the OIPN model group (B) were relatively disordered and had a loose structure.

[0184] HE staining can visually observe the pathological morphological changes of the skin and dorsal root ganglion (DRG) cells of the rats' soles. The skin and DRG cells of the OIPN model group (B) were obviously disordered, loosely structured, with smaller nuclei, and significantly increased inflammatory cell infiltration. Suspected apoptotic cells were visible, which was very different from the skin and DRG cells of normal rats, that is, L-OHP can cause disorder, damage and apoptosis of the skin and DRG cells of the rats' soles. After treatment, it was found that all three groups of drugs had significant effects, which could make the skin and DRG cells arranged regularly and the cells returned to normal size. The effect of the three was ranked as follows: the effect of methylcobalamin + Huoxue Huayu Fang was better than that of methylcobalamin, and the effect of methylcobalamin was better than that of Huoxue Huayu Fang.

[0185] From the above comparison results, it can be learned that the Huoxue Huayu recipe can effectively prevent and repair the damage of L-OHP to the skin and dorsal root ganglia of the OIPN rat model, thereby achieving the effect of resisting nerve cell damage.

[0186] In summary, the topical Chinese medicine composition for treating peripheral neuropathy caused by platinum drugs provided by the present invention can solve the problems of high treatment cost, more side effects and poor efficacy when using drugs such as methylcobalamin, reduced glutathione, amifostine, lipoic acid, calcium magnesium mixture and ganglioside to treat OIPN in the prior art, thereby reducing the side effects generated during the treatment of OIPN and improving the treatment effect of OIPN.

[0187] Those skilled in the art should understand that those skilled in the art can implement the above-mentioned variations by combining the prior art and the above-mentioned embodiments, which will not be described in detail here. Such variations do not affect the essential content of the present invention, and will not be described in detail here.

[0188] The above describes the preferred embodiments of the present invention. It should be understood that the present invention is not limited to the above-mentioned specific embodiments, and the devices and structures that are not described in detail should be understood to be implemented in a common manner in the art; any technician familiar with the art can make many possible changes and modifications without departing from the technical solution of the present invention, or modify them into equivalent embodiments with equivalent changes, which does not affect the essential content of the present invention. Therefore, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of protection of the technical solution of the present invention.

Claims

1. A Chinese medicine composition for external use for treating peripheral neurotoxicity caused by platinum drugs, It is characterized in that The invention comprises astragalus, angelica, vinegar-sweet Trillium, vinegar-sweet Curcuma, cinnamon twig, Polygonum multiflorum and Pheretima; the mass ratio of the astragalus, angelica, vinegar-sweet Trillium, vinegar-sweet Curcuma, cinnamon twig, Polygonum multiflorum and Pheretima is 6:3:2:2:2:4:

2.

2. The Chinese medicine composition for external use for treating peripheral neurotoxicity caused by platinum drugs according to claim 1, It is characterized in that The weight of the Astragalus is 180g; the weight of the Angelica is 90g; the weight of the vinegar-cured Trillium is 60g; the weight of the vinegar-cured Curcuma is 60g; the weight of the cinnamon twig is 60g; the weight of the Polygonum multiflorum is 120g; and the weight of the Pheretima is 60g.

3. A method for preparing a Chinese medicine composition for external use for treating peripheral neurotoxicity caused by platinum drugs as claimed in any one of claims 1 to 2, It is characterized in that The following steps are involved: S101: preparing a Chinese medicine composition for external use, comprising 180 g of Astragalus, 90 g of Angelica, 60 g of Vinegar Trillium, 60 g of Vinegar Curcuma, 60 g of Cinnamomum cassia, 120 g of Rhizoma Cyathulae and 60 g of Pheretima; S102: soaking all the Chinese medicines included in the prepared external Chinese medicine composition in 2000 ml of cold water, boiling them for the first time at 80° C., boiling them for 30 minutes, and filtering them for the first time to obtain a first medicine liquid and medicine residues; S103: Replace 1000 ml of water, put the medicinal residue into the replaced water, and boil again at 80° C. After boiling for 30 minutes, filter again to obtain a second medicinal solution; S104: Mix the first medicinal liquid and the second medicinal liquid to obtain a decoction.

4. The method for preparing the external Chinese medicine composition for treating peripheral neurotoxicity caused by platinum drugs as claimed in claim 3, It is characterized in that In step S102, the Chinese medicine is immersed in cold water for 30 minutes.